Purpose of Review
According to an Endocrine Society Clinical Practice Guideline published in June 2010, testosterone replacement therapy (TRT) should be administered only to men who are hypogonadal with documented low testosterone level on two morning measurements. This recommendation was based on previous studies that did not show an increased risk in cardiovascular events with TRT. In contrast, recent studies did show an increased risk which prompted the FDA to investigate further.
Multiple studies suggested an increased risk in cardiovascular events among groups of men prescribed TRT.
There is recent evidence that TRT can be associated with higher cardiovascular risks, while these risks are still not well established, and more well-designed trials are needed. Physicians should always be cautious when prescribing TRT to their patients. Potential risks should be discussed with each patient, and TRT requires regular monitoring to help minimize side effects.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
• Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682–96. doi:10.1111/j.1742-1241.2010.02355. This review summarizes the current understanding of male hypogonadism, with particular reference to the needs of the primary care physician.
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536–59.
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–43. doi:10.1210/jc.2006-0401. This study presents the prevalence of psychosomatic symptoms and metabolic risk factors accumulated with decreasing androgen levels.
Morgentaler A, Khera M, Maggi M, Zitzmann M. Commentary: who is a candidate for testosterone therapy? A synthesis of international expert opinions. J Sex Med. 2014;11(7):1636–45.
Advisory Committee Industry Briefing Document Testosterone Replacement Therapy. Meeting on September 17, 2014. Date accessed November 30, 2016. Available at: http://www.fda.gov/downloads/AdvisoryCommittee/…/UCM412537.pdf.
AndroGel 1% Package Insert. Date accessed November 30, 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c506aaa3-04f8-4eb1-8dc4-e964cdd08e7f.
AndroGel 1.62% Package Insert. Date accessed November 30, 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8677ba5b-8374-46cb-854c-403972e9ddf3.
Axiron Package Insert. Date accessed November 30, 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6e9cbce2-6e73-400f-9333-421a42afa3ae.
Testim Package Insert. Date accessed November 30, 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f2aae1f-898d-4955-be31-678e0cf85395.
Testosterone Cypionate Injection Package Insert. Date accessed November 30, 2016. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7b57b68-dca6-4df2-b3f2-7017d7b69f17.
• Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–98. This study compares AndroGel to other testosterone preparations in different aspects.
• Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88:2673–81. This study compared the pharmacokinetics and treatment effectiveness of a topical testosterone gel (AA2500) at two concentrations, 50 mg/d and 100 mg/d, to a testosterone patch and placebo gel in 406 hypogonadal men.
• Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, et al. Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578–83. This study presents the effect of TRT on mood and energy level in hypogonadal men.
• Aminorroaya A, Kelleher S, Conway AJ, Ly LP, Handelsman DJ. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men. Eur J Endocrinol. 2005;152:881–6. This study demonstrates a positive relationship between adequacy of testosterone replacement and BMD in men with overt organic androgen deficiency.
• Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82:2386–90. This study illustrates that testosterone therapy increases BMD in hypogonadal men regardless of age.
• Dean JD, McMahon CG, Guay AT, Morgentaler A, Althof SE, Becher ER, et al. The international society for sexual medicine’s process of care for the assessment and management of testosterone deficiency in adult men. J Sex Med. 2015;12:1660–86. This is evidenced-based recommendations for the diagnosis and treatment of testosterone deficiency.
• Diver MJ, Imtiaz KE, Ahmad AM, et al. Diurnal rhythm of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those of young men. Clin Endocrinol. 2003;58:710–7. This study suggests that the diurnal rhythm in these indices of androgen status is maintained in fit, healthy men into the 7th decade of life.
• Fernández-Balsells HM, Murad MH, Melanie L, Lampropulos JF, Albuquerque F, Erwin PJ, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560–75. This is a systematic review and meta-analyses of testosterone trials that evaluates the adverse effects of testosterone treatment in men.
• Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39. This is a systematic review and meta-analysis of randomized trials that assesses the effect of testosterone use on cardiovascular events and risk factors in men with different degrees of androgen deficiency.
The Endocrine Society. The risk of cardiovascular events in men receiving testosterone therapy: an endocrine society statement. Feb 7, 2014. Date accessed November 23, 2016. Available at: (https://www.endocrine.org/~/media/endosociety/Files/Advocacy and Outreach/Position Statements/Other Statements/The Risk of Cardiovascular Events in Men Receiving Testosterone Therapy.pdf).
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. Date accessed November 23, 2016. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm.
World Health Organization (WHO). Global status report on noncommunicable diseases 2014. 2014; 1-302. Available at: http://www.who.int/nmh/publications/ncd-status-report-2014/en/.
Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: expanding the spectrum of prescription drug misuse. Med J Aust. 2013;199(8):548–51.
• Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829–36. This study concluded that there is an increased cardiovascular risk associated with TRT.
• Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi:10.1371/journal.pone.0085805. This is a cohort study of the risk of acute non-fatal myocardial infarction following an initial TT prescription in a large health-care database. This study concluded that there is an increased cardiovascular risk associated with TRT.
• Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363:109–22. This study concluded that there is an increased cardiovascular risk associated with TRT.
• Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108. This study concluded that there is an increased cardiovascular risk associated with TRT.
•• Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90(2):224–51. This article reviews literature on TRT and cardiovascular risks.
• Barrett-Connor EL. Testosterone and risk factors for cardiovascular disease in men. Diabetes Metab. 1995;21(3):156–61. This discusses the cause versus effect controversy, regarding low testosterone levels in men with coronary heart disease, as well as the concerns over the use of testosterone replacement therapy in middle aged and elderly men.
• Khaw KT, Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. J Hypertens. 1988;6(4):329–32. This study shows that systolic and diastolic blood pressure is inversely correlated with testosterone levels.
• Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96(10):3007–19. doi:10.1210/jc.2011-1137. This is a systematic review and meta-analysis of published studies that evaluates the association between endogenous testosterone and mortality.
• Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011;58(16):1674–81. doi:10.1016/j.jacc.2011.07.019. This study shows that serum total testosterone and sex hormone-binding globulin (SHBG) levels can predict cardiovascular (CV) events in community-dwelling elderly men.
• Corona G. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol. 2011;165:687–701. doi:10.1530/EJE-11-0447. This evaluates whether testosterone replacement therapy improves cardiovascular parameters in subjects with known cardiovascular diseases.
Copenhagen Study Group for Liver Diseases. Testosterone treatment of men with alcoholic cirrhosis: a double-blind study. Hepatology. 1986;6(5):807–13.
• Baillargeon J, Urban RJ, Kuo YF, et al. Risk of myocardial infarction in older men receiving testosterone therapy. Ann Pharmacother. 2014;48(9):1138–44. This study evaluates the risk of myocardial infarction in a population-based cohort of older men receiving intramuscular testosterone.
Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. Int J Cardiol. 1998;63(2):161–4.
Dobrzycki S, Serwatka W, Nadlewski S, et al. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Investig. 2003;50(3-4):162–9.
Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75(3):282–8.
Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725–33.
Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab. 2004;89(12):5920–6.
Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821–5.
Haring R, Völzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010;31(12):1494–501.
Lerchbaum E, Pilz S, Boehm BO, Grammer TB, Obermayer-Pietsch B, März W. Combination of low free testosterone and low vitamin D predicts mortality in older men referred for coronary angiography. Clin Endocrinol (Oxf). 2012;77(3):475–83.
Khaw KT, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation. 2007;116(23):2694–701.
Vikan T, Johnsen SH, Schirmer H, Njølstad I, Svartberg J. Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromsø study. Eur J Epidemiol. 2009;24(6):289–95.
Mårin P, Holmäng S, Gustafsson C, et al. Androgen treatment of abdominally obese men. Obes Res. 1993;1(4):245–51.
Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93(1):139–46.
Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–93.
Jones TH, Arver S, Behre HM, et al. TIMES2 investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828–37.
Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–503.
Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of Meeting September 18, 2014. Date accessed November 23, 2016. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-adcom/documents/document/ucm424069.pdf.
Kloner RA, Carson III C, Dobs A, Kopecky S, Mohler III ER. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67(5):545–57. doi:10.1016/j.jacc.2015.12.005.
•• Morgentaler A, Zitzmann M, Traish AM, Fox AW, Hugh Jones T, Maggi M, et al. Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. Mayo Clin Proc. 2016;91(7):881–96. This addresses concerns regarding testosterone deficiency and TRT.
Conflict of Interest
Ahmed Elsherbiny, Matthew Tricomi, and Hari Kumar Dandapantula declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Ischemic Heart Disease
About this article
Cite this article
Elsherbiny, A., Tricomi, M., Bhatt, D. et al. State-of-the-Art: a Review of Cardiovascular Effects of Testosterone Replacement Therapy in Adult Males. Curr Cardiol Rep 19, 35 (2017). https://doi.org/10.1007/s11886-017-0838-x
- Sexual dysfunction
- Erectile dysfunction
- Coronary artery disease
- Myocardial infarction